Extracorporeal membrane oxygenation-hemostatic complications

Transfusion Medicine Reviews

Volumn 29, Issue 2, 2015, Pages 90-101

  Murphy, Deirdre A ^a,b   Hockings, Lisen E ^a,b   Andrews, Robert K ^b   Aubron, Cecile ^b   Gardiner, Elizabeth E ^b   Pellegrino, Vincent A ^a,b   Davis, Amanda K ^a  

^a ALFRED HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Anticoagulants; Disseminated intravascular coagulation; Extracorporeal membrane oxygenation; Fibrinolysis; Hemorrhage; Hemostasis; Thrombosis

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; ANTICOAGULANT AGENT; HEPARIN; HIRUDIN DERIVATIVE; HIRULOG; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD PUMP; BLOOD TRANSFUSION; CARDIOGENIC SHOCK; CENTRAL VENOARTERIAL EXTRACORPOREAL OXYGENATION; DISSEMINATED INTRAVASCULAR CLOTTING; EXTRACORPOREAL OXYGENATION; FIBRINOLYSIS; HEART FUNCTION; HEMOLYSIS; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPERFIBRINOLYSIS; LUNG CIRCULATION; MEMBRANE OXYGENATOR; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PERIPHERAL VENOARTERIAL EXTRACORPOREAL OXYGENATION; REVIEW; THORAX SURGERY; THROMBOCYTOPENIA; THROMBOELASTOGRAPHY; THROMBOSIS; THROMBUS DEPOSITION; VENOARTERIAL EXTRACORPOREAL OXYGENATION; VENOVENOUS EXTRACORPOREAL OXYGENATION; VON WILLEBRAND DISEASE; ADVERSE EFFECTS; BLOOD CLOTTING TEST; BLOOD RHEOLOGY; CARDIAC OUTPUT, LOW; CARDIAC TAMPONADE; CHEMICALLY INDUCED; DEVICES; HEMORRHAGE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; PROCEDURES; RESPIRATORY INSUFFICIENCY; VON WILLEBRAND DISEASES;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CARDIAC OUTPUT, LOW; CARDIAC TAMPONADE; EXTRACORPOREAL MEMBRANE OXYGENATION; HEMOLYSIS; HEMORHEOLOGY; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECOMBINANT PROTEINS; RESPIRATORY INSUFFICIENCY; THROMBOSIS; VON WILLEBRAND DISEASES;

EID: 84927092190     PISSN: 08877963     EISSN: 15329496     Source Type: Journal    
DOI: 10.1016/j.tmrv.2014.12.001     Document Type: Review

References (125)

1. Hill J.D., O'Brien T.G., Murray J.J., Dontigny L., Bramson M.L., Osborn J.J., et al. Prolonged extracorporeal oxygenation for acute post-traumatic respiratory failure (shock-lung syndrome). N Engl J Med 1972, 286:629-634.
2. Bartlett R.H., Roloff D.W., Cornell R.G., Andrews A.F., Dillon P.W., Zwischenberger J.B. Extracorporeal circulation in neonatal respiratory failure: a prospective randomized study. Pediatrics 1985, 76:479-487.
3. O'Rourke P.P., Crone R.K., Vacanti J.P., Ware J.H., Lillehei C.W., Parad R.B., et al. Extracorporeal membrane oxygenation and conventional medical therapy in neonates with persistent pulmonary hypertension of the newborn: a prospective randomized study. Pediatrics 1989, 84:957-963.
4. UK Collaborative ECMO Trial Group UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. Lancet 1996, 348:75-82.
5. Hubmayr R.D., Farmer J.C. Should we "rescue" patients with 2009 influenza A(H1N1) and lung injury from conventional mechanical ventilation?. Chest 2010, 137:745-747.
6. Noah M.A., Peek G.J., Finney S.J., Griffiths M.J., Harrison D.A., Grieve R., et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A (H1N1). JAMA 2011, 306:1659-1668.
7. Peek G.J., Mugford M., Tiruvoipati R., Wilson A., Allen E., Thalanany M.M., et al. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 2009, 374:1351-1363.
8. Pham T., Combes A., Rozé H., Chevret S., Mercat A., Roch A., et al. Extracorporeal membrane oxygenation for pandemic influenza A (H1N1)-induced acute respiratory distress syndrome: a cohort study and propensity-matched analysis. Am J Respir Crit Care Med 2013, 187:276-285.
9. Strueber M. Extracorporeal support as a bridge to lung transplantation. Curr Opin Crit Care 2010, 16:69-73.
10. Peek G.J., Killer H.M., Reeves R., Sosnowski A.W., Firmin R.K. Early experience with a polymethyl pentene oxygenator for adult extracorporeal life support. ASAIO J 2002, 48:480-482.
11. Davies A., Jones D., Bailey M., Beca J., Bellomo R., Blackwell N., et al. Extracorporeal membrane oxygenation for 2009 influenza A (H1N1) acute respiratory distress syndrome. JAMA 2009, 302:1888-1895.
12. Patroniti N., Zangrillo A., Pappalardo F., Peris A., Cianchi G., Braschi A., et al. The Italian ECMO network experience during the 2009 influenza A (H1N1) pandemic: preparation for severe respiratory emergency outbreaks. Intensive Care Med 2011, 37:1447-1457.
13. Chen Y.-S., Lin J.-W., Yu H.-Y., Ko W.-J., Jerng J.-S., Chang W.-T., et al. Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: an observational study and propensity analysis. Lancet 2008, 372:554-561.
14. Chen Y.S., Chao A., Yu H.Y., Ko W.J. Analysis and results of prolonged resuscitation in cardiac arrest patients rescued by extracorporeal membrane oxygenation. J Am Coll Cardiol 2003, 41:197-203.
15. Shin T.G., Choi J.-H., Jo I.J., Sim M.S., Song H.G., Jeong Y.K., et al. Extracorporeal cardiopulmonary resuscitation in patients with inhospital cardiac arrest: a comparison with conventional cardiopulmonary resuscitation. Crit Care Med 2011, 39:1-7.
16. Aubron C., Cheng A.C., Pilcher D., Leong T., Magrin G., Cooper D.J., et al. Factors associated with outcomes of patients on extracorporeal membrane oxygenation support: a 5-year cohort study. Crit Care 2013, 17:R73.
17. Brodie D., Bacchetta M. Extracorporeal membrane oxygenation for ARDS in adults. N Engl J Med 2011, 365:1905-1914.
18. Rastan A.J., Lachmann N., Walther T., Doll N., Gradistanac T., Gommert J.F., et al. Autopsy findings in patients on postcardiotomy extracorporeal membrane oxygenation (ECMO). Int J Artif Organs 2006, 29:1121-1131.
19. Oliver W.C. Anticoagulation and coagulation management for ECMO. Semin Cardiothorac Vasc Anesth 2009, 13:154-175.
20. Garcia J.P., Iacono A., Kon Z.N., Griffith B.P. Ambulatory extracorporeal membrane oxygenation: a new approach for bridge-to-lung transplantation. J Thorac Cardiovasc Surg 2010, 139:e137-e139.
21. Mangi A.A., Mason D.P., Yun J.J., Murthy S.C., Pettersson G.B. Bridge to lung transplantation using short-term ambulatory extracorporeal membrane oxygenation. J Thorac Cardiovasc Surg 2010, 140:713-715.
22. Olsson K.M., Simon A., Strueber M., Hadem J., Wiesner O., Gottlieb J., et al. Extracorporeal membrane oxygenation in nonintubated patients as bridge to lung transplantation. Am J Transplant 2010, 10:2173-2178.
23. MacLaren G., Combes A., Bartlett R.H. Contemporary extracorporeal membrane oxygenation for adult respiratory failure: life support in the new era. Intensive Care Med 2011, 38:210-220.
24. Khoshbin E., Roberts N., Harvey C., Machin D., Killer H., Peek G.J., et al. Poly-methyl pentene oxygenators have improved gas exchange capability and reduced transfusion requirements in adult extracorporeal membrane oxygenation. ASAIO J 2005, 51:281-287.
25. Müller T., Philipp A., Luchner A., Karagiannidis C., Bein T., Hilker M., et al. A new miniaturized system for extracorporeal membrane oxygenation in adult respiratory failure. Crit Care 2009, 13:R205.
26. Lehle K., Philipp A., Gleich O., Holzamer A., Müller T., Bein T., et al. Efficiency in extracorporeal membrane oxygenation-cellular deposits on polymethypentene membranes increase resistance to blood flow and reduce gas exchange capacity. ASAIO J 2008, 54:612-617.
27. Horton S., Thuys C., Bennett M., Augustin S. Experience with the Jostra Rotaflow and QuadroxD oxygenator for ECMO. Perfusion 2004, 19:17-23.
28. Reul H.M., Akdis M. Blood pumps for circulatory support. Perfusion 2000, 15:295-311.
29. Muntean W. Coagulation and anticoagulation in extracorporeal membrane oxygenation. Artif Organs 1999, 23:979-983.
30. Chapter 5. ECMO-extracorporeal cardiopulmonary support in critical care, Ann Arbor 2012, 75-86. G. Annich, W.R. Lynch, G. MacLaren, J.M. Wilson, R.H. Bartlett (Eds.).
31. Lubnow M., Philipp A., Dornia C., Schroll S., Bein T., Creutzenberg M., et al. d-Dimers as an early marker for oxygenator exchange in extracorporeal membrane oxygenation. J Crit Care 2014, 29:473.e1-5.
32. Cuker A. Clinical and laboratory diagnosis of heparin-induced thrombocytopenia: an integrated approach. Semin Thromb Hemost 2014, 40:106-114.
33. Lee G.M., Arepally G.M. Heparin-induced thrombocytopenia. Hematology Am Soc Hematol Educ Program 2013, 2013:668-674.
34. Warkentin T.E. HIT paradigms and paradoxes. J Thromb Haemost 2011, 9(Suppl 1):105-117.
35. Crowther M., Cook D., Guyatt G., Zytaruk N., McDonald E., Williamson D., et al. Heparin-induced thrombocytopenia in the critically ill: interpreting the 4Ts test in a randomized trial. J Crit Care 2014, 29:470.e7-15.
36. Gu Y.J., van Oeveren W., Akkerman C., Boonstra P.W., Huyzen R.J., Wildevuur C.R. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993, 55:917-922.
37. Feyrer R., Harig F., Cesnjevar R. Bioline or safeline treatment of CPB circuits?. Cardiovasc Eng 2003, 8(1/2):79-84.
38. Sakiyama-Elbert S.E. Incorporation of heparin into biomaterials. Acta Biomater 2014, 10(4):1581-1587.
39. Pappalardo F., Maj G., Scandroglio A., Sampietro F., Zangrillo A., Koster A. Bioline heparin-coated ECMO with bivalirudin anticoagulation in a patient with acute heparin-induced thrombocytopenia: the immune reaction appeared to continue unabated. Perfusion 2009, 24:135-137.
40. Beiderlinden M., Treschan T., Görlinger K., Peters J. Argatroban in extracorporeal membrane oxygenation. Artif Organs 2007, 31:461-465.
41. Mejak B., Giacomuzzi C., Heller E., You X., Ungerleider R., Shen I., et al. Argatroban usage for anticoagulation for ECMO on a post-cardiac patient with heparin-induced thrombocytopenia. J Extra Corpor Technol 2004, 36:178-181.
42. Young G., Yonekawa K.E., Nakagawa P., Nugent D.J. Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuits. Perfusion 2004, 19:283-288.
43. Koster A., Weng Y., Böttcher W., Gromann T., Kuppe H., Hetzer R. Successful use of bivalirudin as anticoagulant for ECMO in a patient with acute HIT. Ann Thorac Surg 2007, 83:1865-1867.
44. Cegarra-Sanmartín V., González-Rodríguez R., Paniagua-Iglesias P., Santamaría-Ortiz A., Cueva L.F., Galán-Serrano J., et al. Fondaparinux as a safe alternative for managing heparin-induced thrombocytopenia in postoperative cardiac surgery patients. J Cardiothorac Vasc Anesth 2014, 28:1020-1024.
45. Bauer C., Vichova Z., Ffrench P., Hercule C., Jegaden O., Bastien O., et al. Extracorporeal membrane oxygenation with danaparoid sodium after massive pulmonary embolism. Anesth Analg 2008, 106:1101-1103.
46. Dager W.E., Gosselin R.C., Yoshikawa R., Owings J.T. Lepirudin in heparin-induced thrombocytopenia and extracorporeal membranous oxygenation. Ann Pharmacother 2004, 38:598-601.
47. Balasubramanian S.K., Tiruvoipati R., Chatterjee S., Sosnowski A., Firmin R.K. Extracorporeal membrane oxygenation with lepirudin anticoagulation for Wegener's granulomatosis with heparin-induced thrombocytopenia. ASAIO J 2005, 51:477-479.
48. Kelton J.G., Arnold D.M., Bates S.M. Nonheparin anticoagulants for heparin-induced thrombocytopenia. N Engl J Med 2013, 368:737-744.
49. Dyke C.M., Smedira N.G., Koster A., Aronson S., McCarthy H.L., Kirshner R., et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006, 131:533-539.
50. Linkins L.-A., Dans A.L., Moores L.K., Bona R., Davidson B.L., Schulman S., et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141:e495S-e530S.
51. Bembea M.M., Schwartz J.M., Shah N., Colantuoni E., Lehmann C.U., Kickler T., et al. Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. ASAIO J 2013, 59:63-68.
52. MacLaren G., Combes A., Bartlett R. Contemporary extracorporeal membrane oxygenation for adult respiratory failure: life support in the new era. Intensive Care Med 2012, 38:210-220.
53. Despotis G.J., Avidan M.S., Hogue C.W. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 2001, 72:S1821-S1831.
54. Esper S.A., Levy J.H., Waters J.H., Welsby I.J. Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. Anesth Analg 2014, 118:731-743.
55. ELSO anticoagulation guidelines 2014, 1-17. ELSO Registry (Ed.).
56. Sohn N., Marcoux J., Mycyk T., Krahn J., Meng Q. The impact of different biocompatible coated cardiopulmonary bypass circuits on inflammatory response and oxidative stress. Perfusion 2009, 24:231-237.
57. de Vroege R., Huybregts R., van Oeveren W., van Klarenbosch J., Linley G., Mutlu J., et al. The impact of heparin-coated circuits on hemodynamics during and after cardiopulmonary bypass. Artif Organs 2005, 29:490-497.
58. de Vroege R., van Oeveren W., van Klarenbosch J., Stooker W., Huybregts M.A.J.M., Hack C.E., et al. The impact of heparin-coated cardiopulmonary bypass circuits on pulmonary function and the release of inflammatory mediators. Anesth Analg 2004, 1586-1594.
59. Olson S.T., Björk I. Regulation of thrombin activity by antithrombin and heparin. Semin Thromb Hemost 1994, 20:373-409.
60. Arnold P., Jackson S., Wallis J., Smith J., Bolton D., Haynes S. Coagulation factor activity during neonatal extra-corporeal membrane oxygenation. Intensive Care Med 2001, 27:1395-1400.
61. Niebler R.A., Christensen M., Berens R., Wellner H., Mikhailov T., Tweddell J.S. Antithrombin replacement during extracorporeal membrane oxygenation. Artif Organs 2011, 35:1024-1028.
62. Agati S., Ciccarello G., Salvo D., Turla G., Undar A., Mignosa C. Use of a novel anticoagulation strategy during ECMO in a pediatric population: single-center experience. ASAIO J 2006, 52:513-516.
63. Wong T.E., Huang Y.-S., Weiser J., Brogan T.V., Shah S.S., Witmer C.M. Antithrombin concentrate use in children: a multicenter cohort study. J Pediatr 2013, 163:1329-1334.
64. Bembea M.M., Annich G., Rycus P., Oldenburg G., Berkowitz I., Pronovost P. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation. Pediatr Crit Care Med 2013, 14:e77-e84.
65. Whiting D., DiNardo J.A. TEG and ROTEM: technology and clinical applications. Am J Hematol 2014, 89:228-232.
66. Paden M.L., Conrad S.A., Rycus P.T., Thiagarajan R.R., Registry E.L.S.O. Extracorporeal Life Support Organization Registry Report 2012. ASAIO J 2013, 59:202-210.
67. Zangrillo A., Landoni G., Biondi-Zoccai G., Greco M., Greco T., Frati G., et al. A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc 2013, 15:172-178.
68. Kumar T.K.S., Zurakowski D., Dalton H., Talwar S., Allard-Picou A., Duebener L.F., et al. Extracorporeal membrane oxygenation in postcardiotomy patients: factors influencing outcome. J Thorac Cardiovasc Surg 2010, 140:330-332.
69. Rastan A.J., Dege A., Mohr M., Doll N., Falk V., Walther T., et al. Early and late outcomes of 517 consecutive adult patients treated with extracorporeal membrane oxygenation for refractory postcardiotomy cardiogenic shock. J Thorac Cardiovasc Surg 2010, 139:302-311.
70. Golding L.A., Crouch R.D., Stewart R.W., Novoa R., Lytle B.W., McCarthy P.M., et al. Postcardiotomy centrifugal mechanical ventricular support. Ann Thorac Surg 1992, 54:1059-1063.
71. Extracorporeal membrane oxygenation for 2009 influenza A (H1N1) acute respiratory distress syndrome. JAMA 2009, 302:1888-1895.
72. Vanderschueren S., De Weerdt A., Malbrain M., Vankersschaever D., Frans E., Wilmer A., et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000, 28:1871-1876.
73. Crowther M.A., Cook D.J., Meade M.O., Griffith L.E., Guyatt G.H., Arnold D.M., et al. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care 2005, 20:348-353.
74. Williamson D.R., Albert M., Heels-Ansdell D., Arnold D.M., Lauzier F., Zarychanski R., et al. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: frequency, risk factors, and outcomes. Chest 2013, 144:1207-1215.
75. Lieberman L., Bercovitz R.S., Sholapur N.S., Heddle N.M., Stanworth S.J., Arnold D.M. Platelet transfusions for critically ill patients with thrombocytopenia. Blood 2014, 123:1146-1151.
76. Greinacher A., Selleng K. Thrombocytopenia in the intensive care unit patient. ASH Education Program Book 2010, 135-143.
77. Despotis G., Eby C., Lublin D.M. A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery. Transfusion 2008, 48:2S-30S.
78. Levi M., Cate Ten H. Disseminated intravascular coagulation. N Engl J Med 1999, 341:586-592.
79. Levi M., Meijers J.C. DIC: which laboratory tests are most useful. Blood Rev 2011, 25:33-37.
80. Bernard G.R., Vincent J.-L., Laterre P.-F., LaRosa S.P., Dhainaut J.-F., Lopez-Rodriguez A., et al. Efficacy and safety of recombinant human activated protein c for severe sepsis. N Engl J Med 2001, 344:699-709.
81. Gando S., Nanzaki S., Sasaki S., Kemmotsu O. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation. Thromb Haemost 1998, 79:1111-1115.
82. Taylor F.B., Toh C.H., Hoots W.K., Wada H. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001, 86:1327-1330.
83. Hunt B.J. Bleeding and coagulopathies in critical care. N Engl J Med 2014, 370:847-859.
84. Hunt B.J., Parratt M.S., Segal H.C., Sheikh S., Kallis P., Yacoub M. Activation of coagulation and fibrinolysis during cardiothoracic operations. Ann Thorac Surg 1998, 65:712-718.
85. Wood A.J.J., Mannucci P.M. Hemostatic drugs. N Engl J Med 1998, 339:245-253.
86. Downard C.D., Betit P., Chang R.W., Garza J.J., Arnold J.H., Wilson J.M. Impact of Amicar on hemorrhagic complications of ECMO: a ten-year review. J Pediatr Surg 2003, 38:1212-1216.
87. Wilson J.M., Bower L.K., Fackler J.C., Beals D.A., Bergus B.O., Kevy S.V. Aminocaproic acid decreases the incidence of intracranial hemorrhage and other hemorrhagic complications of ECMO. J Pediatr Surg 1993, 28:536-541.
88. Horwitz J.R., Cofer B.R., Warner B.W., Cheu H.W., Lally K.P. A multicenter trial of 6-aminocaproic acid (Amicar) in the prevention of bleeding in infants on ECMO. J Pediatr Surg 1998, 33:1610-1613.
89. Heyde E.C. Gastrointestinal bleeding in aortic stenosis (letter). N Engl J Med 1958, 259:196.
90. Warkentin T.E., Moore J.C., Morgan D.G. Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link?. Lancet 1992, 340:35-37.
91. Vincentelli A., Susen S., Le Tourneau T., Six I., Fabre O., Juthier F., et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med 2003, 349:343-349.
92. Crow S., John R., Boyle A., Shumway S., Liao K., Colvin-Adams M., et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg 2009, 137:208-215.
93. Miller L.W. The development of the von Willebrand syndrome with the use of continuous flow left ventricular assist devices: a cause-and-effect relationship. J Am Coll Cardiol 2010, 56:1214-1215.
94. Uriel N., Pak S.W., Jorde U.P., Jude B., Susen S., Vincentelli A., et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 2010, 56:1207-1213.
95. Meyer A.L., Malehsa D., Bara C., Budde U., Slaughter M.S., Haverich A., et al. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail 2010, 3:675-681.
96. Dittmer R., Abd Müller H.E., Schaeper H., Schneppenheim S. Spectrum of the acquired von Willebrand syndrome in a large cohort of patients diagnosed in a single institution. Blood 2013, 122:3607-7.
97. Nguyen T., Hui S.K., Soundar E.P., Nguyen K.T., Teruya M., Cruz M.A., et al. Abstract 452: loss of large von Willebrand factor multimers during pediatric extracorporeal membrane oxygenation support. Pediatr Crit Care Med 2014, 15(4 Suppl.):S103-S104.
98. Pasala S., Fiser R.T., Stine K.C., Swearingen C.J., Prodhan P. von Willebrand factor multimers in pediatric extracorporeal membrane oxygenation support. ASAIO J 2014, 60:419-423.
99. Heilmann C., Zieger B., Benk C., Trummer G., Nakamura L., Schlensak C., et al. Acquired von Willebrand syndrome in patients with extra-corporeal life support (ECLS) or membrane oxygenation (ECMO). Thorac Cardiovasc Surg 2011, 59(1 Suppl.):V136.
100. Bilen O., Loftis L., Teruya J. Severe thrombotic and bleeding complications in a baby with heterozygous factor V Leiden and acquired von Willebrand disease on ECMO. J Extra Corpor Technol 2011, 43:64-69.
101. Heilmann C., Geisen U., Beyersdorf F., Nakamura L., Benk C., Trummer G., et al. Acquired von Willebrand syndrome in patients with extracorporeal life support (ECLS). Intensive Care Med 2011, 38:62-68.
102. Al-Tamimi M., Tan C.W., Qiao J., Pennings G.J., Javadzadegan A., Yong A.S.C., et al. Pathologic shear triggers shedding of vascular receptors: a novel mechanism for down-regulation of platelet glycoprotein VI in stenosed coronary vessels. Blood 2012, 119:4311-4320.
103. Gardiner E.E., Andrews R.K. Plasma sGPVI: changing levels in human disease. Thromb Res 2014, 133:306-307.
104. Federici A.B., Budde U., Castaman G., Rand J.H., Tiede A. Current diagnostic and therapeutic approaches to patients with acquired von Willebrand syndrome: a 2013 update. Semin Thromb Hemost 2013, 39:191-201.
105. Federici A.B., Budde U., Rand J.H. Acquired von Willebrand syndrome 2004: international registry. Hamostaseologie 2004, 24:50-55.
106. Tiede A., Rand J.H., Budde U., Ganser A., Federici A.B. How I treat the acquired von Willebrand syndrome. Blood 2011, 117:6777-6785.
107. Critical bleeding massive transfusion 2011, 1-113. [Available from: http://www.blood.gov.au/pbm-module-1. Accessed 19/10/2014]. National Blood Authority, Australia (Ed.).
108. Simpson E., Lin Y., Stanworth S., Birchall J., Doree C., Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2012, 3:CD005011.
109. Lin Y., Stanworth S., Birchall J., Doree C., Hyde C. Use of recombinant factor VIIa for the prevention and treatment of bleeding in patients without hemophilia: a systematic review and meta-analysis. CMAJ 2011, 183:E9-E19.
110. Lin Y., Moltzan C.J., Anderson D.R. National Advisory Committee on Blood and Blood Products. The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework. Transfus Med 2012, 22:383-394.
111. Repessé X., Au S.M., Bréchot N., Trouillet J.-L., Leprince P., Chastre J., et al. Recombinant factor VIIa for uncontrollable bleeding in patients with extracorporeal membrane oxygenation: report on 15 cases and literature review. Crit Care 2013, 17:R55.
112. Niebler R.A., Punzalan R.C., Marchan M., Lankiewicz M.W. Activated recombinant factor VII for refractory bleeding during extracorporeal membrane oxygenation. Pediatr Crit Care Med 2010, 11:98-102.
113. Syburra T., Lachat M., Genoni M., Wilhelm M.J. Fatal outcome of recombinant factor VIIa in heart transplantation with extracorporeal membrane oxygenation. Ann Thorac Surg 2010, 89:1643-1645.
114. Bui J.D., Despotis G.D., Trulock E.P., Patterson G.A., Goodnough L.T. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 2002, 124:852-854.
115. Chalwin R.P., Tiruvoipati R., Peek G.J. Fatal thrombosis with activated factor VII in a paediatric patient on extracorporeal membrane oxygenation. Eur J Cardiothorac Surg 2008, 34:685-686.
116. Marasco S.F., Preovolos A., Lim K., Salamonsen R.F. Thoracotomy in adults while on ECMO is associated with uncontrollable bleeding. Perfusion 2007, 22:23-26.
117. Joshi V., Harvey C., Nakas A., Waller D.A., Peek G.J., Firmin R. The need for thoracic surgery in adult patients receiving extracorporeal membrane oxygenation: a 16-year experience. Perfusion 2013, 28:328-332.
118. Arlt M., Philipp A., Voelkel S., Rupprecht L., Mueller T., Hilker M., et al. Extracorporeal membrane oxygenation in severe trauma patients with bleeding shock. Resuscitation 2010, 81:804-809.
119. Betrus C., Remenapp R., Charpie J., Kudelka T., Brophy P., Smoyer W.E., et al. Enhanced hemolysis in pediatric patients requiring extracorporeal membrane oxygenation and continuous renal replacement therapy. Ann Thorac Cardiovasc Surg 2007, 13:378-383.
120. Schaer D.J., Buehler P.W., Alayash A.I., Belcher J.D., Vercellotti G.M. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 2013, 121:1276-1284.
121. Leverett L.B., Hellums J.D., Alfrey C.P., Lynch E.C. Red blood cell damage by shear stress. Biophys J 1972, 12:257-273.
122. Kawahito S., Maeda T., Motomura T., Ishitoya H., Takano T., Nonaka K., et al. Hemolytic characteristics of oxygenators during clinical extracorporeal membrane oxygenation. ASAIO J 2002, 48:636-639.
123. Horton A.M., Butt W. Pump-induced haemolysis: is the constrained vortex pump better or worse than the roller pump?. Perfusion 1992, 7:103-108.
124. Lehle K., Philipp A., Müller T., Schettler F., Bein T., Schmid C., et al. Flow dynamics of different adult ECMO systems: a clinical evaluation. Artif Organs 2014, 38:391-398.
125. Toomasian J.M., Bartlett R.H. Hemolysis and ECMO pumps in the 21st century. Perfusion 2011, 26:5-6.